Christopher Nevala-Plagemann, Thierry Conroy, Ignacio Garrido-Laguna
{"title":"Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’","authors":"Christopher Nevala-Plagemann, Thierry Conroy, Ignacio Garrido-Laguna","doi":"10.1038/s41571-024-00953-4","DOIUrl":null,"url":null,"abstract":"<p>We appreciate the interest of Wainberg and O’Reilly in our recently published News & Views article that critiques the design and reporting of results from the NAPOLI 3 trial (Nevala-Plagemann, C. & Garrido-Laguna, I. NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? <i>Nat. Rev. Clin. Oncol</i>. <b>21</b>, 567–568 (2024))<sup>1</sup>. In their Correspondence (Wainberg, Z. A. & O’Reilly, E. M. NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3. <i>Nat. Rev. Clin. Oncol</i>. https://doi.org/10.1038/s41571-024-00952-5 (2024))<sup>2</sup>, they raise several points that we would like to address.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":81.1000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-024-00953-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
We appreciate the interest of Wainberg and O’Reilly in our recently published News & Views article that critiques the design and reporting of results from the NAPOLI 3 trial (Nevala-Plagemann, C. & Garrido-Laguna, I. NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? Nat. Rev. Clin. Oncol. 21, 567–568 (2024))1. In their Correspondence (Wainberg, Z. A. & O’Reilly, E. M. NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3. Nat. Rev. Clin. Oncol. https://doi.org/10.1038/s41571-024-00952-5 (2024))2, they raise several points that we would like to address.
我们感谢 Wainberg 和 O'Reilly 对我们最近发表的《新闻与观点》（News & Views）一文的关注，该文批评了 NAPOLI 3 试验的设计和结果报告（Nevala-Plagemann, C. & Garrido-Laguna, I. NALIRIFOX 治疗转移性胰腺腺癌：希望还是炒作？Nat.Rev. Clin.Oncol.21, 567-568 (2024))1.在他们的通信（Wainberg, Z. A. & O'Reilly, E. M. NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3. Nat.Rev. Clin.https://doi.org/10.1038/s41571-024-00952-5 (2024))2，他们提出了几点我们希望解决的问题。
期刊介绍：
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
